Lymphangiogenomics

Receptor Ligand Technologies GmbH (RELIATech) is a post-genomics biotechnology company focused on the discovery and commercialisation of novel technologies and products in the field of receptor ligand interaction. The company is located in Braunschweig, Germany and was founded in 2000 by three leading cell molecular biologists from Israel and Germany. Their research program involved growth factor interactions, tyrosine kinases and signalling pathways involved in tissue remodelling, homeostasis and disease. Signal proteins such as ligands, receptors and kinases are critically involved in the development and the function of all higher organisms and are key regulatory molecules in physiological and path-physiological conditions.

Products and Services

RELIATech has clear focus in proteomics and assay design and provides the following services/products:

• Generation of expression vectors for the E. coli and Baculovirus expression system
• Protein production in E. coli  and insect cells
• Protein production in mammalian cells (CHO, BHK21; bioreactor scale)
• Monoclonal antibody production with hybridomas
• Purification of recombinant proteins and antibodies
• Establishing of ELISA assays for signal proteins
• Creation of soluble and transmembrane receptors constructs for expression
• Ligand-receptor interaction studies

In addition RELIATech sells hundreds of specific molecular research products for angiogenesis, lymphangiogenesis, growth factor and cytokine research:

• Human growth factor and cytokines from insect cells and E. coli (e.g. VEGF165, bFGF, BMP-2, II-3, GM-CSF)
• Selected rat and murine products (e.g. mVEGF164 and rVEGF-C)
• Soluble receptor proteins for inhibition, binding and assay development (e.g. sKDR, sFlt-1, sFLT-4, sFGF-R1-4, sCD105, sLYVE-1)
• ELISA kits for quantitative detection of signal proteins (e.g. sVEGFR-1, VEGF-A, VEGF-C)
• Monoclonal and single chain antibodies (e.g. VEGFR-1/flt-1, VEGFR-2/KDR, VEGFR-3/FLT-4, TIE-1, TIE-2)
• Polyclonal antibodies for vascular research (e.g. FGF-2, PIGF, VEGF-C, VEGF-D, VEGF-A, KDR, Flt-1)
• Polyclonal/monoclonal antibodies for lymphangiogenesis research (e.g. LYVE-1, Prox-1, Podoplanin, VEGFR-3)
• Unique growth factor for vascular biology and lymphangiogenesis (e.g. ovVEGF-E, VEGF121, PIGF-2, VEGF-C)

The full list of new products, related prices and additional information are available under www.reliatech.de.

Business Model

RELIATech is a contractual service and proteomics supply company, that offers specific technologies, services and protein products for customers from academia, research and pharmaceutical industry. RELIATech has series of unique products for angiogenesis and lymphangiogenesis research.

Contact:

Dr. Bernhard Barleon

RELIATech GmbH
Inhoffenstr. 7
38124 Braunschweig
Germany

Phone: +49 - (0)531 - 260 - 1832/-31
Fax: +49 - (0)531 - 260 - 1833
E-Mail: bernhard.barleon(at)reliatech.de
Web: www.reliatech.de